Improving immunotherapy for the treatment of hepatocellular carcinoma: learning from patients and preclinical models
Abstract Hepatocellular carcinoma (HCC), the third cause of cancer-related deaths worldwide, continues to present significant therapeutic challenges. Despite significant therapeutic advancement in the last decade, the efficacy of systemic treatments for patients with advanced HCC remains unsatisfact...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-04-01
|
| Series: | npj Gut and Liver |
| Online Access: | https://doi.org/10.1038/s44355-025-00018-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849735020812435456 |
|---|---|
| author | Romain Desert Fabio Gianonne Antonio Saviano Yujin Hoshida Mathias Heikenwälder Pierre Nahon Thomas F. Baumert |
| author_facet | Romain Desert Fabio Gianonne Antonio Saviano Yujin Hoshida Mathias Heikenwälder Pierre Nahon Thomas F. Baumert |
| author_sort | Romain Desert |
| collection | DOAJ |
| description | Abstract Hepatocellular carcinoma (HCC), the third cause of cancer-related deaths worldwide, continues to present significant therapeutic challenges. Despite significant therapeutic advancement in the last decade, the efficacy of systemic treatments for patients with advanced HCC remains unsatisfactory. While the clinical introduction of immune checkpoint inhibitors has improved response rates and overall survival, their clinical success remains still limited. Here we provide a comprehensive review of current and emerging strategies aimed at enhancing the efficacy of immunotherapy for the treatment of HCC. Both clinical studies conducted in patients as well as studies in preclinical models have markedly advanced our understanding of resistance as well as uncovered novel approaches to overcome resistance. Recent progress is paving the way for improved efficacy and safety of novel approaches that will improve the dismal prognosis of patients with advanced HCC. |
| format | Article |
| id | doaj-art-2cb680c0cb3c40c08947553a21db7a4d |
| institution | DOAJ |
| issn | 3004-9806 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Gut and Liver |
| spelling | doaj-art-2cb680c0cb3c40c08947553a21db7a4d2025-08-20T03:07:40ZengNature Portfolionpj Gut and Liver3004-98062025-04-012111510.1038/s44355-025-00018-yImproving immunotherapy for the treatment of hepatocellular carcinoma: learning from patients and preclinical modelsRomain Desert0Fabio Gianonne1Antonio Saviano2Yujin Hoshida3Mathias Heikenwälder4Pierre Nahon5Thomas F. Baumert6Inserm, Institute of Translational Medicine and Liver DiseaseInserm, Institute of Translational Medicine and Liver DiseaseInserm, Institute of Translational Medicine and Liver DiseaseDivision of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical CenterDivision of Chronic Inflammation and Cancer, German Cancer Research Centre Heidelberg (DKFZ)AP-HP, Hôpitaux Universitaires Paris Seine Saint-Denis, Liver Unit, University Sorbonne Paris Nord, UFR SMBHInserm, Institute of Translational Medicine and Liver DiseaseAbstract Hepatocellular carcinoma (HCC), the third cause of cancer-related deaths worldwide, continues to present significant therapeutic challenges. Despite significant therapeutic advancement in the last decade, the efficacy of systemic treatments for patients with advanced HCC remains unsatisfactory. While the clinical introduction of immune checkpoint inhibitors has improved response rates and overall survival, their clinical success remains still limited. Here we provide a comprehensive review of current and emerging strategies aimed at enhancing the efficacy of immunotherapy for the treatment of HCC. Both clinical studies conducted in patients as well as studies in preclinical models have markedly advanced our understanding of resistance as well as uncovered novel approaches to overcome resistance. Recent progress is paving the way for improved efficacy and safety of novel approaches that will improve the dismal prognosis of patients with advanced HCC.https://doi.org/10.1038/s44355-025-00018-y |
| spellingShingle | Romain Desert Fabio Gianonne Antonio Saviano Yujin Hoshida Mathias Heikenwälder Pierre Nahon Thomas F. Baumert Improving immunotherapy for the treatment of hepatocellular carcinoma: learning from patients and preclinical models npj Gut and Liver |
| title | Improving immunotherapy for the treatment of hepatocellular carcinoma: learning from patients and preclinical models |
| title_full | Improving immunotherapy for the treatment of hepatocellular carcinoma: learning from patients and preclinical models |
| title_fullStr | Improving immunotherapy for the treatment of hepatocellular carcinoma: learning from patients and preclinical models |
| title_full_unstemmed | Improving immunotherapy for the treatment of hepatocellular carcinoma: learning from patients and preclinical models |
| title_short | Improving immunotherapy for the treatment of hepatocellular carcinoma: learning from patients and preclinical models |
| title_sort | improving immunotherapy for the treatment of hepatocellular carcinoma learning from patients and preclinical models |
| url | https://doi.org/10.1038/s44355-025-00018-y |
| work_keys_str_mv | AT romaindesert improvingimmunotherapyforthetreatmentofhepatocellularcarcinomalearningfrompatientsandpreclinicalmodels AT fabiogianonne improvingimmunotherapyforthetreatmentofhepatocellularcarcinomalearningfrompatientsandpreclinicalmodels AT antoniosaviano improvingimmunotherapyforthetreatmentofhepatocellularcarcinomalearningfrompatientsandpreclinicalmodels AT yujinhoshida improvingimmunotherapyforthetreatmentofhepatocellularcarcinomalearningfrompatientsandpreclinicalmodels AT mathiasheikenwalder improvingimmunotherapyforthetreatmentofhepatocellularcarcinomalearningfrompatientsandpreclinicalmodels AT pierrenahon improvingimmunotherapyforthetreatmentofhepatocellularcarcinomalearningfrompatientsandpreclinicalmodels AT thomasfbaumert improvingimmunotherapyforthetreatmentofhepatocellularcarcinomalearningfrompatientsandpreclinicalmodels |